Jubilant Pharmova Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to the National Stock Exchange of India Limited and BSE Limited on August 1, 2026, disclosing robust environmental, social, and governance (ESG) performance metrics. The filing, mandated under Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, underscores the company’s commitment to sustainable practices, highlighted by an NSE Sustainability score of 72/100 placing it in the ‘Leader’ category and a Crisil ESG rating of 63/100.

The report was signed by Naresh Kapoor, Company Secretary, and covers consolidated disclosures for Jubilant Pharmova Limited and its subsidiaries. TUV SUD South Asia Pvt. Ltd. provided reasonable assurance for the BRSR Core attributes, verifying the accuracy of key sustainability indicators. The filing details the company’s progress against specific sustainability goals set for FY26, including targets for energy efficiency, waste management, and employee well-being.

Environmental Performance and Targets

Jubilant Pharmova reported significant achievements in its environmental sustainability goals for FY26. The company exceeded its target for renewable energy usage, achieving 41.6% of total purchased power from renewable sources against a target of 25.62%. Specific greenhouse gas (GHG) emissions were reduced to 7.86 tCO2e/Cr. INR, surpassing the target of 11.69 tCO2e/Cr. INR. Additionally, specific water consumption decreased to 70.9 m3/Cr. INR, well below the target of 88.75 m3/Cr. INR.

The company implemented three new energy-saving projects in its Indian operations during FY26, contributing to a reduction of 1,378.5 tCO2 in GHG emissions. Total Scope 1 and Scope 2 emissions intensity stood at 0.79 gmCO2e/INR, down from 1.03 gmCO2e/INR in FY25. All Indian manufacturing sites operate as Zero Liquid Discharge (ZLD) facilities, complying with local regulatory requirements.

Social Metrics and Employee Well-being

On the social front, Jubilant Pharmova maintained a workforce of 3,786 employees and 2,600 workers at the end of FY26. Women constituted 26% of the total employee count and 18% of the worker count. The company reported a turnover rate of 18% for permanent employees and 10% for permanent workers in FY26, compared to 22% and 11% respectively in FY25.

Employee training initiatives saw increased engagement, with 9.7 training man-days per employee per year achieved against a target of 6.7. The company reported two complaints related to sexual harassment under the POSH Act in FY26, both of which were resolved, with zero complaints upheld. Gross wages paid to females accounted for 12.7% of total wages paid, up from 9.7% in FY25.

Governance and Stakeholder Engagement

Jubilant Pharmova’s Board of Directors oversees sustainability through the CSR & Sustainability Committee, which reviews performance bi-annually. The company adheres to international standards including ISO 14001, ISO 9001, ISO 27001, and ISO 45001 across its facilities. In terms of stakeholder engagement, the company received 802 customer complaints regarding delivery of essential services in FY26, with 71 pending resolution at year-end. No penalties or fines were reported from regulatory authorities during the period.

What the Numbers Show

The divergence between revenue stability and improved efficiency metrics indicates successful operational optimization. While the report notes stable revenues due to business diversification, the significant reduction in specific GHG emissions (from a target of 11.69 to an actual of 7.86 tCO2e/Cr. INR) and water consumption suggests that growth is not coming at the cost of increased resource intensity. This decoupling of operational scale from environmental impact is a critical indicator of mature sustainability practices in the pharmaceutical manufacturing sector.

Jubilant Pharmova Limited has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Priyavrat Bhartia and Mr. Arjun Shanker Bhartia as Managing Director and Joint Managing Director, respectively. The re-appointments are proposed for a period of three years effective from June 1, 2026, to May 31, 2029. The resolutions require approval as the remuneration payable may exceed five per cent of the net profits, and aggregate remuneration to all directors may exceed ten per cent of net profits.

The remote e-voting period commenced on July 19, 2026, at 9:00 A.M. (IST) and will conclude on August 17, 2026, at 5:00 P.M. (IST). Shareholders whose names appear in the Register of Members or the list of Beneficial Owners as on the cut-off date of July 10, 2026, are entitled to vote. The Board appointed Mr. Rupinder Singh Bhatia, Practicing Company Secretary, as the Scrutinizer for the process. Physical copies of the postal ballot notice are not being dispatched; communication is exclusively through the remote e-voting system.

Re-appointment Details

The Board approved the re-appointments at its meeting held on May 22, 2026. Mr. Priyavrat Bhartia, aged 49, has been associated with the Board since May 2017 and has served as Managing Director since June 1, 2023. Mr. Arjun Shanker Bhartia, aged 39, has been on the Board since May 2017 and was re-designated as Joint Managing Director effective June 1, 2023. The terms include a salary and perquisites of up to ₹7,50,00,000 per annum for each director.

Financial Performance

The explanatory statement provided the financial performance of the Company for the financial year 2025-26. The standalone profit after tax was reported at ₹632 million, while the consolidated profit after tax stood at ₹3,975 million.

The notice states that during FY 2025-26, the Company transferred its Active Pharmaceutical Ingredients (API) business to a wholly owned subsidiary, classifying it as a discontinued operation in standalone financial statements. This resulted in inadequate profits from continuing operations at the standalone level, though the consolidated financial performance was not adversely impacted.